eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple endocrine neoplasia type 1 |
| Comorbidity | C0206698|cholangiocarcinoma |
| Sentences | 1 |
| PubMedID- 20670085 | In this study we aimed to find the maximally tolerated dose (mtd) of a two-week schedule of fixed dose rate (fdr) gemcitabine (g), oxaliplatin (o) and capecitabine (c), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (cc). |
Page: 1